Status:
COMPLETED
Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Lung Transplantation
Antibody Mediated Rejection
Eligibility:
All Genders
18+ years
Brief Summary
The aim is to compare the quantitative parameters of de novo anti-HLA DQ Donor Specific Antibodies (DSA), determined at the time of their discovery by surface plasmon resonance (SPR), between recipien...
Detailed Description
After lung transplantation the production of de novo DSA directed against HLA-DQ molecules is associated with CLAD and graft loss. The most used assay for serum DSA detection is the Single Antigen Lum...
Eligibility Criteria
Inclusion
- Age 18 years and older
- Patient transplanted between 01/01/2001 and 31/07/2016
- Patient with immunodominant anti-HLA DQ de novo DSA developed before 08/2016
- Patient for who sufficient remaining serum quantity is available in usual care biobank
- non-opposition of the patient
Exclusion
- preformed DSA at the transplantation;
- Non immunodominant DQ DSA ;
- Insufficient serum quantity in usual care biobank
- Inability to determine the date of DSA apparition at around one year
- opposition of the patient
Key Trial Info
Start Date :
March 14 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 8 2025
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT03474536
Start Date
March 14 2018
End Date
April 8 2025
Last Update
July 4 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Bordeaux
Bordeaux, France
2
Hôpital Marie Lannelongue
Le Plessis-Robinson, France, 92350
3
Hôpital Européen Georges Pompidou
Paris, France, 75015
4
AP-HP Hôpital Bichat
Paris, France, 75877